Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000731709 | SCV000859557 | uncertain significance | not provided | 2018-02-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000802202 | SCV000942021 | benign | Qualitative or quantitative defects of dysferlin | 2024-12-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002535234 | SCV003541861 | uncertain significance | Inborn genetic diseases | 2022-12-28 | criteria provided, single submitter | clinical testing | The c.1310C>T (p.T437M) alteration is located in exon 14 (coding exon 14) of the DYSF gene. This alteration results from a C to T substitution at nucleotide position 1310, causing the threonine (T) at amino acid position 437 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001830617 | SCV002079796 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2019-10-28 | no assertion criteria provided | clinical testing |